Written and edited by internationally recognised leaders in the field, the new edition of the Oxford Textbook of Oncology has been fully revised and updated, taking into consideration the advancements in each of the major therapeutic areas, and representing the multidisciplinary management of cancer.
Structured in six sections, the book provides an accessible scientific basis to the key topics of oncology, examining how cancer cells grow and function, as well as discussing the aetiology of cancer, and the general principles governing modern approaches to oncology treatment. The book examines the challenges presented by the treatment of cancer on a larger scale within population groups, and the importance of recognising and supporting the needs of individual patients, both during and after treatment.
A series of disease-oriented, case-based chapters, ranging from acute leukaemia to colon cancer, highlight the various approaches available for managing the cancer patient, including the translational application of cancer science in order to personalise treatment. The advice imparted in these cases has relevance worldwide, and reflects a modern approach to cancer care. The Oxford Textbook of Oncology provides a comprehensive account of the multiple aspects of best practice in the discipline, making it an indispensable resource for oncologists of all grades and subspecialty interests.
Edited by:
David J. Kerr,
Daniel G Haller (University of Pennsylvania Health System,
Philadelphia,
PA,
USA),
Cornelius J. H. van de Velde,
Michael Baumann,
Nagahiro Saijo
Imprint: Oxford University Press
Country of Publication: United Kingdom
Edition: 3rd Revised edition
Dimensions:
Height: 282mm,
Width: 227mm,
Spine: 39mm
Weight: 2.460kg
ISBN: 9780199656103
ISBN 10: 019965610X
Pages: 1040
Publication Date: 11 February 2016
Audience:
Professional and scholarly
,
Undergraduate
Format: Hardback
Publisher's Status: Active
Section 1: Hallmarks of Cancer 1: Douglas Hanahan and Robert A. Weinberg: The hallmarks of cancer 2: Shujuan Liu and Ahmed Ashour Ahmed: Growth factors and uncontrolled proliferation 3: Stefan Knapp: Cell signalling pathways 4: Simon Carr and Nicholas La Thangue: Cell cycle control 5: Amanda S. Coutts, Sandra Maniam, and Nicholas La Thangue: Cancer cell death 6: Yull E. Arriaga and Arthur E. Frankel: Angiogenesis 7: Andrew P. Mazar, Andrey Ugolkov, Jack Henkin, Richard Ahn, and Thomas V. O'Halloran: Invasion and metastases 8: Sir Walter Bodmer and Jenny Wilding: Genetic instability 9: E. Dikomey, K. Borgmann, M. Kriegs, W. Mansour, C. Petersen, and T. Rieckmann: DNA repair after oncological therapy 10: Andreas Trumpp: Biology of cancer stem cells 11: Richard D Kennedy, Manuel Salto-Tellez, D. Paul Harkin, and Patrick G Johnston: Biomarker identification and clinical validation 12: Campbell SD Roxburgh and Donald C McMillan: Cancer, immunity, and inflammation 13: Cameron Snell, Kevin C Gatter, Adrian L Harris, Francesco Pezzella: Cancer and metabolism Section 2: Etiology and Epidemiology of Cancer 14: Jonathan Samet: Smoking and cancer 15: Chris Boshoff: Viruses 16: Paula A. Oliveira: Chemical carcinogens 17: Klaus Trott: Radiation 18: Ellen Kampman and Franzel van Duijnhoven: Body fatness, physical activity, diet, and other lifestyle factors Section 3: Principles of Oncology 19: PG Boelens, CBM van den Broek, and CJH van de Velde: Practice points for surgical oncology 20: Annekatrin Singer, Stephanie E. Combs, Jurgen Debus, and Michael Baumann: Practice points for radiation oncology 21: David Kerr, Daniel Haller, and Jaap Verweij: Principles of chemotherapy 22: David N Church, Rachel S Midgley, and David J Kerr: Delivery of multidisciplinary cancer care 23: Michael Ong and Udai Banerji: Principles of clinical pharmacology: Introduction to pharmacokinetics and pharmacodynamics 24: Dan Sargeant and Qian Shi: Design and analysis of clinical trials 25: Eric A. Singer: Medical ethics in oncology 26: Jeffrey Peppercorn: Health economic assessment of cancer therapy Section 4: Population Health 27: Masoud Samiei: Cancer control: The role of national plans 28: Sarah Goltz and Julian Lob-Levyt: Cancer prevention: Vaccination 29: Hans-Joerg Senn, Nadir Arber, and Dirk Schrijvers: Cancer prevention: Chemoprevention 30: Andrew Evans, Simon Herrington, and Robert Steele: Population cancer screening 31: Henry T. Lynch, Carrie L. Snyder, and Jane F. Lynch (deceased): Familial cancer syndromes and genetic counselling Section 5: Support for the cancer patient 32: David Hui and Eduardo Bruera: Supportive palliative care 33: Neil Aaronson and Peter Fayers: Quality of life 34: Rachel L. Yung and Ann H. Partridge: Cancer survivorship and rehabilitation Section 6: Disease 35: Christine Chung, Andreas Dietz, Vincent Gregoire, Marco Guzzo, Marc Hamoir, Rene Leemans, Jean-Louis Lefebvre, Lisa Licitra, Adel El-Naggar, Brian O?Sullivan, Bing Tan, Vincent Vandecaveye, Vincent Vander Poorten, Jan Vermorken, and Michelle Williams: Cancer of the head and neck 36: Eric Van Cutsem, Christophe M. Deroose, Piet Dirix, Karin Haustermans, Tony Lerut, Philippe Nafteux, Hans Prenen, and Xavier Sagaert: Oesophageal cancer 37: Hideaki Bando, Takahiro Kinoshita, Yasutoshi Kuboki, Atsushi Ohtsu, and Kohei Shitara: Gastric cancer 38: Regina Beets-Tan, Bengt Glimelius, and Lars Pahlman: Rectal cancer 39: John Zalcberg, Stephen Fox, Alexander Heriot, Jon Knowles, Sam Ngan, Michael Michael, Kathryn Field, and Iris Nagtegaal: Colon cancer 40: J. Weitz, M.W. Buchler, Paul D Sykes, John P Neoptolemos, Eithne Costello, Christopher M Halloran, Frank Bergmann, Peter Schirmacher, Ulrich Bork, Stefan Fritz, Jens Werner, Thomas Brunner, Elizabeth Smyth, David Cunningham, Brian R. Untch, and Peter J. Allen: Pancreatic cancer 41: Graeme J Poston, Nicholas Stern, Jonathan Evans, Priya Healey, Daniel Palmer, and Mohandas K. Mallath: Hepatobiliary cancer 42: H. Richard Alexander, Jr., Dario Baratti, Terence C. Chua, Marcello Deraco, Raffit Hassan, Marzia Pennati, Federica Perrone, Paul H. Sugarbaker, Anish Thomas, Keli Turner, Tristan D. Yan and Nadia Zaffaroni: Peritoneal mesothelioma 43: Martine Piccart, Toral Gathani, Dimitrios Zardavas, Hatem A. Azim Jr., Christos Sotiriou, Giuseppe Viale, Emiel J T Rutgers, Mechthild Krause, Monica Arnedos, Suzette Delaloge, Fabrice Andre, and Felipe Ades: Cancer of the breast 44: Richard Poetter, Shujuan Liu, Bolin Liu, Sebastien Gouy, Sigurd Lax, Eric Leblanc, Philippe Morice, Fabrice Narducci, Alexander Reinthaller, Maximilian P Schmid, Catherine Uzan, and Pauline Wimberger: Gynaecological cancers 45: John Fitzpatrick, Asif Muneer , Jean de la Rosette, and Thomas Powles: Genitourinary cancer 46: Rafal Dziadziuszko, Michael Baumann, Tetsuya Mitsudomi, Keith M. Kerr, Solange Peters, and Stefan Zimmermann: Lung cancer 47: Rebecca Butof, Axel Denz, Gustavo Baretton, Jan Stoehlmacher-Williams, and Michael Baumann: Neoplasms of the thymus 48: Andrea S. Wolf, Assunta De Rienzo, Raphael Bueno, Lucian R. Chirieac, Joseph Corson, Elizabeth H. Baldini, David Jackman, Ritu Gill, Walter Weder, Isabelle Opitz, Ann S. Adams, and David J. Sugarbaker: Pleural mesothelioma 49: John F Thompson, Richard A Scolyer, and Richard F Kefford: Skin cancer: melanoma 50: Diona L. Damian, Richard A. Scolyer, Graham Stevens, Alexander Menzies, and John F. Thompson: Skin cancer: non-melonoma 51: Adele K. Fielding, Charles G. Mullighan, Dieter Hoelzer, Eytan M. Stein, Ghada Zakout, Martin S. Tallman, Ross Levine, Yishai Ofran, Jacob M. Rowe, and Ross L. Levine: Acute leukemia 52: Hemant Malhotra, Lalit Kumar, Pankaj Malhotra, Devendra Hiwase, and Ravi Bhatia: Chronic leukemias 53: Charlotte Pawlyn, Faith Davies, and Gareth Morgan: Myeloma 54: Frank Kroschinsky, Friedrich Stoelzel, Stefano A. Pileri, Bjoern Chapuy, Rainer Ordemann, Christian Gisselbrecht, Tim Illidge, David C. Hodgson, Mary K. Gospodarowicz, Christina Schutze, and Gerald Wulf: Lymphomas 55: Alessandro Gronchi, Angelo P. Dei Tos, and Paolo G. Casali: Sarcomas of the soft tissue 56: Puneet Plaha, Allyson Parry, Pieter Pretorius, Michael Brada, Olaf Ansorge, and Claire Blessing: Cancer of the central nervous system 57: Daniel G. Ezra, Geoffrey E. Rose, Jacob Pe'er, Sarah Coupland, S. Seregard, G.P.M. Luyten, and Annette C. Moll: Cancer of the eye and orbit 58: David Kerr, Andrew Weaver, Anthony P. Weetman, Oliver Gimm, Ashley Grossman, Petra Sulentic, Bertram Wiedenmann, Ulrich-Frank Pape, John Wass, Angela Rogers, and W de Herder: Endocrine cancers 59: Nicholas Pavlidis and George Pentheroudakis: Cancer of unknown primary site Index
David Kerr has made a sustained and internationally recognised contribution to cancer care and research in the field of medical oncology over the past three decades. He has published over 400 papers in high profile journals, authored over twenty books and has been awarded four prestigious, international research prizes, including the NHS's first Nye Bevan award for Innovation. His scientific standing has been recognised by election as Fellow of the Royal College of Physicians, Fellow of Academy of Medical Sciences, President of the European society of Medical Oncology (2009-2011) and Founding Fellow of the European Academy of Cancer Sciences.
Reviews for Oxford Textbook of Oncology
Review from previous edition The Oxford Textbook of Oncology is a classic and fresh approach to the field. It is a must for all libraries and all those who like to have a single up-to-date reference book that contains sufficient detail for the clinician in all subspecialties: surgery and chapters are sufficiently details to provide a reference for trainees in the field. Oncology, Volume 63, 2002 The Oxford Textbook of Oncology covers virtually the entire spectrum of malignant diseases in adults and children. It meets very high editorial and production standards: the organization, illustrations, and eye-pleasing typography are outstanding... I have high praise for this textbook. NEJM, Volume 347, Number 2, 2002 Under new editorship, the second edition is far more than an updated version of the first...the prose in the Oxford Textbook is exemplary...this textbook is unique among its peers in giving the sense that the authors are addressing the reader personally...an exception level of qualityELRespect for the evidence-based medicine is apparent throughout the text...illustrative and anatomical drawing...of remarkable high quality...excellent discussion of doctor-patient communication in relation OT genetic counselling, psychological issues, and terminal cancers. JAMA, Volume 287, Issue 24, 2002 An outstanding work and an impressive achievement. Journal of the National Cancer Institute, 2002 A landmark referenceELIt sets new standards for publishing in oncology offering a ground-breaking innovative approach to the filed combined with the quality, accuracy , and intellectual rigour you have come to expect from the world's most prestigious reference publisher. Biomedicine and Pharmacotherapy, 2002 This comprehensive textbook of oncology is the first new major textbook on cancer to appear in a decade and is designed for a broad audience of clinicians, oncologists in training, and academics. The coverage is comprehensive...The overall appearance of the book is outstanding. It is a welcome combination of epidemiology, aspects of basic science, pharmacology and radiation therapy that trainees will fine a nice change...should enjoy a wide readership...because of its appealing design and comprehensive approach to oncology. It is the most user-friendly comprehensive text currently available. The pathology, basic science, epidemiology, and radiation therapy sections are all presented with extreme clarity. Doody's Journal , 2002 I recommend this book highly to all oncology and oncologists in training as a thorough, informative, and readable reference. Every large intuitional library and every oncology library should have it. NEJM, 2002
